Nabriva Therapeutics(NBRVF)
$0.010.00 (0.00%)
NBRVF
Nabriva Therapeutics financials statements
$0.01
At close:0.00 (0.00%)
Nabriva Therapeutics (NBRVF) Ratios
1,010 Followers
Nabriva Therapeutics Ratios
NBRVF's free cash flow for Q2 2023 was $511.00K. For the 2023 fiscal year, NBRVF's free cash flow was decreased by $-22.00 and operating cash flow was $511.00K. See a summary of the company’s cash flow.
| Ratios | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.13 | 3.59 | 3.09 | 5.48 | 6.11 |
| Quick Ratio | 0.78 | 2.94 | 2.77 | 5.44 | 6.11 |
| Cash Ratio | 0.45 | 2.13 | 2.23 | 5.17 | 5.73 |
| Solvency Ratio | -2.00 | -1.77 | -2.71 | -1.55 | -2.73 |
| Operating Cash Flow Ratio | -1.33 | -2.67 | -3.85 | -4.32 | -4.08 |
| Short-Term Operating Cash Flow Coverage | -7.60 | -15.82 | -34.95 | 0.00 | 0.00 |
| Net Current Asset Value | $ 2.63M | $ 52.71M | $ 31.92M | $ 38.33M | $ 66.97M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.10 | 0.13 | 0.37 | 0.21 |
| Debt-to-Equity Ratio | 1.59 | 0.15 | 0.23 | 0.84 | 0.35 |
| Debt-to-Capital Ratio | 0.61 | 0.13 | 0.19 | 0.46 | 0.26 |
| Long-Term Debt-to-Capital Ratio | 0.11 | 0.07 | 0.15 | 0.46 | 0.26 |
| Financial Leverage Ratio | 9.65 | 1.52 | 1.76 | 2.28 | 1.61 |
| Debt Service Coverage Ratio | -10.17 | -10.27 | -17.75 | -21.63 | -858.17 |
| Interest Coverage Ratio | -79.50 | -53.86 | -38.11 | -21.81 | -859.96 |
| Debt to Market Cap | 2.05 | 4.87 | 15.83 | 122.37 | 122.88 |
| Interest Debt Per Share | 2.21 | 5.15 | 18.42 | 128.53 | 117.39 |
| Net Debt to EBITDA | 0.13 | 0.84 | 0.50 | 0.65 | 0.69 |
| Profitability Margins | |||||
| Gross Profit Margin | 19.87% | 51.69% | 68.45% | 99.10% | 100.00% |
| EBIT Margin | -153.97% | -176.58% | -1346.65% | -1025.93% | -1763.05% |
| EBITDA Margin | -153.36% | -174.24% | -1330.34% | -1015.99% | -1755.20% |
| Operating Profit Margin | -155.57% | -178.31% | -1315.42% | -1025.93% | -1759.62% |
| Pretax Profit Margin | -155.93% | -179.89% | -1379.45% | -1066.89% | -1765.09% |
| Net Profit Margin | -160.33% | -181.69% | -1382.22% | -1068.20% | -1765.85% |
| Continuous Operations Profit Margin | -160.33% | -181.69% | -1382.22% | -1068.20% | -1765.85% |
| Net Income Per EBT | 102.82% | 101.00% | 100.20% | 100.12% | 100.04% |
| EBT Per EBIT | 100.23% | 100.89% | 104.87% | 103.99% | 100.31% |
| Return on Assets (ROA) | -180.03% | -61.12% | -118.91% | -87.94% | -103.95% |
| Return on Equity (ROE) | -1736.56% | -92.69% | -209.70% | -200.52% | -167.24% |
| Return on Capital Employed (ROCE) | -1333.89% | -82.86% | -165.68% | -102.60% | -123.50% |
| Return on Invested Capital (ROIC) | -617.04% | -77.85% | -157.62% | -102.60% | -123.50% |
| Return on Tangible Assets | -180.04% | -61.14% | -119.07% | -88.03% | -104.04% |
| Earnings Yield | -2244.40% | -3001.88% | -14235.20% | -29353.40% | -59464.15% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.29 | 2.13 | 1.29 | 2.82 | 1.21 |
| Payables Turnover | 5.26 | 3.01 | 0.55 | 0.01 | 0.00 |
| Inventory Turnover | 2.95 | 0.91 | 0.27 | 0.10 | 0.00 |
| Fixed Asset Turnover | 127.39 | 116.81 | 6.55 | 3.13 | 5.71 |
| Asset Turnover | 1.12 | 0.34 | 0.09 | 0.08 | 0.06 |
| Working Capital Turnover Ratio | 1.16 | 0.56 | 0.09 | 0.09 | 0.08 |
| Cash Conversion Cycle | 123.20 | 452.42 | 959.05 | -20680.95 | 301.60 |
| Days of Sales Outstanding | 68.99 | 171.01 | 283.82 | 129.27 | 301.60 |
| Days of Inventory Outstanding | 123.57 | 402.78 | 1340.10 | 3556.14 | 0.00 |
| Days of Payables Outstanding | 69.36 | 121.37 | 664.87 | 24366.36 | 0.00 |
| Operating Cycle | 192.56 | 573.79 | 1623.92 | 3685.41 | 301.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -13.69 | -34.35 | -138.83 | -242.23 | -357.92 |
| Free Cash Flow Per Share | -13.77 | -34.36 | -139.05 | -242.43 | -359.05 |
| Dividend Paid and CapEx Coverage Ratio | -173.99 | -2382.28 | -631.25 | -1178.56 | -317.57 |
| Capital Expenditure Coverage Ratio | -173.99 | -2382.28 | -631.25 | -1178.56 | -317.57 |
| Operating Cash Flow Coverage Ratio | -7.03 | -7.42 | -9.23 | -2.08 | -3.07 |
| Operating Cash Flow to Sales Ratio | -1.03 | -2.19 | -14.19 | -9.28 | -11.19 |
| Free Cash Flow Yield | -1449.11% | -3616.95% | -14636.75% | -25519.13% | -37794.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.04 | -0.03 | -0.01 | -0.00 | -0.00 |
| Price-to-Sales (P/S) Ratio | 0.07 | 0.06 | 0.10 | 0.04 | 0.03 |
| Price-to-Book (P/B) Ratio | 0.77 | 0.03 | 0.01 | 0.01 | 0.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.07 | -0.03 | -0.01 | -0.00 | -0.00 |
| Price-to-Operating Cash Flow Ratio | -0.07 | -0.03 | -0.01 | -0.00 | -0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | 0.08 | 0.80 | 0.50 | 0.65 | 0.68 |
| Enterprise Value | -4.65M | -37.98M | -33.14M | -51.24M | -78.09M |
| EV to EBITDA | 0.08 | 0.80 | 0.50 | 0.65 | 0.68 |
| EV to Sales | -0.13 | -1.40 | -6.59 | -6.61 | -12.01 |
| EV to Free Cash Flow | 0.13 | 0.64 | 0.46 | 0.71 | 1.07 |
| EV to Operating Cash Flow | 0.13 | 0.64 | 0.46 | 0.71 | 1.07 |
| Tangible Book Value Per Share | 1.23 | 30.75 | 64.33 | 138.76 | 311.34 |
| Shareholders’ Equity Per Share | 1.23 | 30.77 | 64.49 | 139.06 | 337.77 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.03 | -0.01 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 13.30 | 15.70 | 9.78 | 26.11 | 31.99 |
| Net Income Per Share | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 |
| Tax Burden | 1.03 | 1.01 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.02 | 1.02 | 1.04 | 1.00 |
| Research & Development to Revenue | 0.40 | 0.46 | 3.00 | 3.41 | 12.66 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 6.42 |
| Stock-Based Compensation to Revenue | 0.06 | 0.12 | 1.04 | 1.26 | 0.00 |
| Income Quality | 0.64 | 1.20 | 1.03 | 0.87 | 0.63 |
Currency in USD

